Chalhub E G, Devivo D C, Volpe J J
Neurology. 1976 May;26(5):494-8. doi: 10.1212/wnl.26.5.494.
Similar movement disorders developed in two 8-year-old retarded children while they were receiving phenytoin. Seizures subsequent to a diphtheria-pertussis-tetanus immunization had developed in each child at 1 to 2 months of age. A static encephalopathy ensued, characterized by mental retardation, ataxia, spasticity, and a mixed seizure disorder. Intermittent dystonia and choreoathetosis developed insidiously while serum phenytoin concentrations were in the therapeutic range. Sustained dystonia and choreoatheosis developed 2 hours after an oral provocation with phenytoin. The baseline abnormalities on the electroencephalogram remained unchanged during the choreoathetosis. Recognizable metabolic abnormalities known to be associated with similar movement disorders were excluded. It was concluded from these studies that the movement disorder is secondary to phenytoin and can occur at therapeutic serum concentrations. Phenytoin is a central anticholinergic agent and a central stimulant of serotonin, and may induce movement disorders as a result of altering these neurotransmitters in the brain. The variable expression of these movement disorders may relate to the nature of the preexisting striatal insult.
两名8岁的智力发育迟缓儿童在服用苯妥英钠期间出现了类似的运动障碍。每名儿童在1至2个月大时因白喉-百日咳-破伤风免疫接种后出现了癫痫发作。随后出现了一种静态脑病,其特征为智力发育迟缓、共济失调、痉挛和混合性癫痫障碍。在血清苯妥英浓度处于治疗范围内时,间歇性肌张力障碍和舞蹈手足徐动症逐渐隐匿出现。口服苯妥英激发试验2小时后出现持续性肌张力障碍和舞蹈手足徐动症。在舞蹈手足徐动症期间,脑电图上的基线异常保持不变。排除了已知与类似运动障碍相关的可识别代谢异常。从这些研究得出的结论是,运动障碍是苯妥英钠的继发结果,并且可在治疗性血清浓度时发生。苯妥英是一种中枢抗胆碱能药物和5-羟色胺的中枢兴奋剂,可能由于改变大脑中的这些神经递质而诱发运动障碍。这些运动障碍的可变表现可能与先前存在的纹状体损伤的性质有关。